



Scientist, Genome Biology
Job code 248DR

Description

Fate Therapeutics is currently seeking a talented and highly motivated scientist with a strong background in Next Generation Sequencing (NGS) and single cell characterization methods to join a multidisciplinary team dedicated to the discovery of novel iPSC derived cellular therapeutics. The candidate will play a key role in NGS method development to perform genomic and transcriptomic characterization on immune cells in the tumor microenvironment including Fate's engineered iPSC derived T and NK cell cancer immunotherapy products. The successful candidate must have knowledge of current genomic engineering techniques (Lentivirus, CRISPR, etc.) as well as strong expertise in genomic and transcriptomic characterization of genetically modified cells using NGS, preferably in a single-cell environment. The position will require innovative thinking, strong independent and collaborative research abilities, and excellent oral and written communication skills. This is a full-time, bench-level position reporting to the Associate Director, Genomics and is located at the Company's corporate headquarters in San Diego, California.

Responsibilities

- Play a key role in the method development for novel single-cell RNA, DNA, and proteogenomic NGS techniques, including the adaptation of recent cutting-edge single cell genomics technologies (10x Genomics, Perturb-seq, CITE-seq, CROP-seq, etc.).
- Work closely with the molecular biology and immunology groups to develop cell-based screening strategies to enable the detection of various genomic perturbations using NGS technologies.
- Use existing and newly developed NGS methods to thoroughly investigate Fate's cellular products and its impacts on the tumor microenvironment.
- Execute robust bioinformatic data analysis workflows to support the analysis of NGS sequencing data.
- Provide biological interpretation of NGS analysis results and present results in a clear and concise manner, to scientific audiences.

Qualifications

- Requires Ph.D. degree and 2+ years postdoctoral training in genetics/genomics, immunology, molecular biology or highly related discipline. Some industry experience is preferred.
- Strong technical background with standard laboratory methods, including flow cytometry; molecular biology and cloning; lentivirus and CRISPR gRNA design are necessary.
- Robust experience in custom NGS method development and library generation is required.
- Experience with primary human cells including iPSC, CD34+, T and NK cells is preferred.
- Hands-on experience with in-depth characterization (RNA-seq, single-cell RNA-seq, multi-dimensional flow cytometry, etc.) of immune cells infiltrating the solid tumor microenvironment is preferred.
- Experience in complex NGS data analysis is preferred.



- Excellent creativity, technical decision-making, and trouble shooting skills.
- Excellent communication and presentation skills is required.

Working Conditions and Physical Requirements

- Will require working with blood and cell lines of human and animal origin
- Will require working with hazardous materials
- 100% on-site work at corporate headquarters in San Diego, CA
- Occasional evening and weekend work will be required

The preceding job description indicates the general nature and level of work performed by employees within this classification. Additional and incidental duties related to the primary duties may be required from time to time.

For consideration send cover letter and resume to: careers@fatetherapeutics.com and reference job code 248DR.

About Fate Therapeutics, Inc.

Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders. The Company is pioneering the development of off-the-shelf cell products using its proprietary induced pluripotent stem cell (iPSC) product platform. The Company's immuno-oncology pipeline is comprised of FATE-NK100, a donor-derived natural killer (NK) cell cancer immunotherapy that is currently being evaluated in three Phase 1 clinical trials, as well as iPSC-derived NK cell and T-cell immunotherapies, with a focus on developing next-generation cell products intended to synergize with checkpoint inhibitor and monoclonal antibody therapies and to target tumor-associated antigens. The Company's immuno-regulatory pipeline includes ProTmune™, a pharmacologically modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease, and a myeloid-derived suppressor cell immunotherapy for promoting immune tolerance in patients with immune disorders. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.